VITA 34 AG Profile Avatar - Palmy Investing

VITA 34 AG

VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous…

Medical - Care Facilities
DE, Leipzig [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 28% Weak
Profitability n.A. n.A.
Fin. Growth 33% Weak
Leverage & Liquidity 17% Weak
Per Share Metrics 0% Bad
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q1 Δ in %
EV/EBITDA 16.29 76.65 65.91
Graham Fair Price -54.14 1.16 2.54
PEG 1080.87 0.23 -0.02
Price/Book -0.37 3.82 3.83
Price/Cash Flow 16.92 32.76 28.02
Prices/Earnings 362.55 -28.31 6.12
Price/Sales 8.13 4.79 4.43
Price/FCF 16.92 32.76 28.02
Naive Interpretation member
01 - Valuation · Weak
Fundamentals

Profitability

Metric Q4 Q1 Δ in %
Gross Profit Margin 11.10 0.38 0.34
Operating Margin -55.01 -0.05 -0.04
ROA -78.36 < 0.005 0.02
ROE 0.16 -0.03 -78.46
ROIC -0.06 -0.02 66.54
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q1 Δ in %
Debt QOQ -0.16 -0.12 -35.27
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ -7.06 -0.41 94.17
EPS QOQ 3.10 -1.21 -60.83
FCF QOQ 2.89 -0.16 -94.54
Revenue QOQ < 0.005 -0.09 -5433.19
Naive Interpretation member
03 - Financial Growth · Weak
Fundamentals

Leverage & Liquidity

Metric Q4 Q1 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 22.71 25.90 14.05
Days Sales Outstanding (DSO) 81.28 77.08 -5.17
Inventory Turnover 3.96 3.48 -12.32
Debt/Capitalization 0.32 0.25 -21.60
Quick Ratio 0.67 0.59 -12.02
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q1 Δ in %
Book Value 1.35 1.34 -1.18
Cash 1.09 0.87 -20.59
Capex -0.04 -0.07 -86.56
Free Cash Flow 0.18 0.16 -15.79
Revenue 1.17 1.06 -8.95
Naive Interpretation member
05 - Per Share Metrics · Bad
Fundamentals

Financial Health

Metric Q4 Q1 Δ in %
Current Ratio 0.73 0.71 -3.21
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA 2.90 2.51 -13.59
Naive Interpretation Member
06 - Financial Health · Bad
End of V3V.DE's Analysis
CIK: - CUSIP: D9506F102 ISIN: DE000A0BL849 LEI: - UEI: -
Secondary Listings
V3V.DE has no secondary listings inside our databases.